.png)
Successful Scientific Engagement Supported by Amplity Insights
Amplity Insights has contributed numerous analyses to-date, including conference-accepted poster presentations, peer-reviewed journal publications and research led studies examining various scientific theses from physician narratives of real-world patient encounters in the U.S. routine care setting.
Want to learn more about our database methodologies and representativeness?
ONCOLOGY
Understanding Reasons for Treatment Disruption of Tyrosine Kinase Inhibitors in NSCLC Patients
Shim, A. 2022. Understanding Treatment Patterns, Disruptions, and Potential Limitations of Tyrosine Kinase Inhibitors in ROS1+ Non-Small Cell Lung Cancer Patients in a Retrospective Review of United States Electronic Medical Transcription Records. ISPOR Europe 2022; Vienna, Austria, and virtual.
Understanding treatment patterns, disruptions, and potential limitations of tyrosine kinase inhibitors in ROS1+ non-small cell lung cancer patients
Shim, A. 2022. Understanding Treatment Patterns, Disruptions, and Potential Limitations of Tyrosine Kinase Inhibitors in ROS1+ Non-Small Cell Lung Cancer Patients in a Retrospective Review of United States Electronic Medical Transcription Records. ISPOR Europe 2022; Vienna, Austria, and virtual.
Healthcare Resource Utilization in NSCLC Patients
Shim, A. 2022. Healthcare Resource Utilization of United States ROS1+ Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: Analysis of Electronic Medical Transcription Records. ISPOR Europe 2022; Vienna, Austria, and virtual.
Healthcare resource utilization of United States ROS1+ non-small cell lung cancer patients treated with tyrosine kinase inhibitors
Shim, A. 2022. Healthcare Resource Utilization of United States ROS1+ Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: Analysis of Electronic Medical Transcription Records. ISPOR Europe 2022; Vienna, Austria, and virtual.
Uptake of the First U.S. Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database
Smoyer, K. 2017. Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Ofce Visits. ISPOR USA 2017; Boston, MA, USA.
Identify physicians’ documentation of Granulocyte Colony-Stimulating Factor (G-CSF) utilization, with a focus on Filgrastim-sndz
Smoyer, K. 2017. Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Ofce Visits. ISPOR USA 2017; Boston, MA, USA.
DIABETES
Prevalence of Hypoglycemia in a Medical Transcription Database
Uzoigwe, C. 2020. 'Assessing Prevalence of Hypoglycemia in a Medical Transcription Database', Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13: 2209–2216.
Assess the prevalence of unrecorded hypoglycemia events by utilizing transcription data and NLP to uncover undiagnosed cases
Uzoigwe, C. 2020. 'Assessing Prevalence of Hypoglycemia in a Medical Transcription Database', Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13: 2209–2216.
RARE DISEASE
Describe demographic, clinical characteristics, and the use of genetic testing and patient support tools/services among RP patients
Patient Characteristics and Use of Genetic Testing and Support Services in Retinitis Pigmentosa
Hautamaki, E. Frequency And Nature Of Patient-reported Outcome Conversations Between Physicians And Patients With Cystic Fibrosis.
Understand the patient journey, path to diagnosis, symptom profile, treatment rationale and related demographic factors in ultrarare disease
Primary Hyperoxaluria Type 1
Hautamaki, E. Frequency And Nature Of Patient-reported Outcome Conversations Between Physicians And Patients With Cystic Fibrosis.
Identification of Generalized Myasthenia Gravis and Antibody Status Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes
Darer, J. 2023. Identification of Generalized Myasthenia Gravis and Antibody Status Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes. MGFA, AANEM 2023; Phoenix, AZ, USA.
To assess the feasibility of identifying meaningful MG clinical subtypes from neurologist clinical progress notes
Darer, J. 2023. Identification of Generalized Myasthenia Gravis and Antibody Status Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes. MGFA, AANEM 2023; Phoenix, AZ, USA.
Real-world Characterization of Challenges Related to the Identification and Management of Myasthenia Gravis Crisis
Darer, J. 2023. Real-world Characterization of Challenges Related to the Identification and Management of Myasthenia Gravis Crisis. MGFA, AANEM 2023; Phoenix, AZ, USA.
To characterize the identification, clinical presentation, and management challenges related to individuals with MG crisis based upon chart review of neurologist clinical progress notes
Darer, J. 2023. Real-world Characterization of Challenges Related to the Identification and Management of Myasthenia Gravis Crisis. MGFA, AANEM 2023; Phoenix, AZ, USA.
Identification of Myasthenia Gravis Exacerbations, Crises, and Symptom Burden Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes
Darer, J. 2023. Identification of Myasthenia Gravis Exacerbations, Crises, and Symptom Burden Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes. MGFA, AANEM 2023; Phoenix, AZ, USA.
To assess the feasibility of identifying symptoms and clinical deterioration for individuals with MG as documented in neurologist clinical progress notes
Darer, J. 2023. Identification of Myasthenia Gravis Exacerbations, Crises, and Symptom Burden Using Rules-Based Natural Language Processing Applied to Neurologist Clinical Notes. MGFA, AANEM 2023; Phoenix, AZ, USA.
NEUROLOGY
Examine the Clinical and Humanistic Burden of Patients With Dravet Syndrome and Lennox-Gastaut Syndrome in the United States
Rao, S. 2023. Analysis of Physician Notes to Examine the Clinical and Humanistic Burden of Patients With Dravet Syndrome and Lennox-Gastaut Syndrome in the United States. American Epilepsy Society (AES) 2023; Orlando, Fl, USA.
Understanding the patient impact of DS/LGS
Rao, S. 2023. Analysis of Physician Notes to Examine the Clinical and Humanistic Burden of Patients With Dravet Syndrome and Lennox-Gastaut Syndrome in the United States. American Epilepsy Society (AES) 2023; Orlando, Fl, USA.
Treatment Patterns of Patients With Dravet Syndrome and Lennox-Gastaut Syndrome
Lu, M. 2023. Antiseizure Medication Treatment Patterns, Reasons for Disruption, and Side Effects for Patients With Dravet Syndrome or Lennox-Gastaut Syndrome: A Retrospective Analysis of US Physician Notes. American Epilepsy Society (AES) 2023; Orlando, Fl, USA.
Understanding treatment patterns and reasons for treatment discontinuation and switching
Lu, M. 2023. Antiseizure Medication Treatment Patterns, Reasons for Disruption, and Side Effects for Patients With Dravet Syndrome or Lennox-Gastaut Syndrome: A Retrospective Analysis of US Physician Notes. American Epilepsy Society (AES) 2023; Orlando, Fl, USA.
Patient Reported Motivations for Medication Switching and/or Adherence Challenges Among Patients Diagnosed With Multiple Sclerosis
Smalarz, A. Patient reported motivations for medication switching and/or adherence challenges among patients diagnosed with Multiple Sclerosis.
Better understand patients’ reason(s) for their adherence and non-adherence, and better understand patients’ reason(s) for switching medications
Smalarz, A. Patient reported motivations for medication switching and/or adherence challenges among patients diagnosed with Multiple Sclerosis.
Reasons for Treatment Discontinuation and Switch in Patients With Epilepsy
Velez, F. 2015. Reasons for treatment discontinuation and switch in patients with epilepsy: a retrospective observational study in a US population. 67th American Academy of Neurology Annual Meeting; Washington DC, USA.
Evaluate patient characteristics associated with antiepileptic drug discontinuations and switches among patients with epilepsy
Velez, F. 2015. Reasons for treatment discontinuation and switch in patients with epilepsy: a retrospective observational study in a US population. 67th American Academy of Neurology Annual Meeting; Washington DC, USA.
AUTOIMMUNE
Feasibility of Use of Medical Transcription Data for Real World Evidence Generation
Narayanan, S. Feasibility Of Use Of Medical Transcription Data For Real World Evidence Generation In The United States (US): A Pilot Study Of Patients With Systemic Lupus Erythematosus (SLE) Initiated On Belimumab.
A pilot study of patients with Systemic Lupus Erythematosus (SLE) initiated on Belimumab
Narayanan, S. Feasibility Of Use Of Medical Transcription Data For Real World Evidence Generation In The United States (US): A Pilot Study Of Patients With Systemic Lupus Erythematosus (SLE) Initiated On Belimumab.
Patient-Reported Outcomes in Cystic Fibrosis
Hautamaki, E. Frequency And Nature Of Patient-reported Outcome Conversations Between Physicians And Patients With Cystic Fibrosis.
Describe the frequency and nature of PRO conversations and the modalities utilized to alleviate disease burden
Hautamaki, E. Frequency And Nature Of Patient-reported Outcome Conversations Between Physicians And Patients With Cystic Fibrosis.
Evaluation of Disease Activity in Patients Diagnosed With Rheumatoid Arthritis
Smalarz, A. Evaluation Of Disease Activity In Patients Diagnosed With Rheumatoid Arthritis: How Often And To What Detail Are Assessments Documented?
Understand documentation of disease activity and impact, reasons for adherence/non-adherence/switching, and physician treatment recommendations
Smalarz, A. Evaluation Of Disease Activity In Patients Diagnosed With Rheumatoid Arthritis: How Often And To What Detail Are Assessments Documented?
PULMONOLOGY
MENTAL HEALTH
Real World Clinicogenomic Evidence Generation for Mental Health Disorders in the United States
Mehta, J. Use Of Medical Transcription Data For Real World Clinicogenomic Evidence Generation For Mental Health Disorders In US.
Assess trends in genomic testing from 2008 to 2017 and understand treatment changes among patients due to testing
